|
US2002102562A1
|
|
Recombinant CMV neutralizing proteins
|
|
AU2249900A
|
|
Composition for inducing a mucosal immune response
|
|
FR2801900A1
|
|
Method for producing adherent animal cells
|
|
FR2797263A1
|
|
Immunostimulant oligonucleotide
|
|
EP1074612A1
|
|
Use of vegetal peptones for DNA vaccine production
|
|
FR2795963A1
|
|
New polynucleotides are useful as vaccines for humans
|
|
WO0000218A1
|
|
Mucosal targeting immunisation
|
|
WO0000216A2
|
|
Use of poxviruses as enhancer of specific immunity
|
|
AU3714499A
|
|
Hepatitis c virus mimotopes
|
|
FR2791895A1
|
|
Use of trehalose to stabilize a liquid vaccine
|
|
EP1035137A1
|
|
Method for the reductive amination of polysaccharides
|
|
EP1034792A1
|
|
Intranasal delivery of pneumococcal polysaccharide vaccines
|
|
FR2785293A1
|
|
Nucleic acids and polypeptides specific to neisseria pathogenic strains
|
|
FR2783170A1
|
|
Immunostimulating emulsion
|
|
FR2781676A1
|
|
Quarter of hiv env gene expression product
|
|
FR2781160A1
|
|
Use of an amphipathic compound to adjust a subunit vaccine
|
|
AU7537598A
|
|
Dna based anti-(helicobacter) vaccine composition
|
|
FR2775983A1
|
|
Viral propagation and multiplication medium and method
|
|
CA2246760A1
|
|
Polysaccharide-peptide-conjugates
|
|
FR2773818A1
|
|
Bacteria lysis process and device
|
